Status:
COMPLETED
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Nicox Ophthalmics, Inc.
Conditions:
Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18-84 years
Phase:
PHASE3
Brief Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle gla...
Eligibility Criteria
Inclusion
- Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
- Qualifying IOP at 3 time points through the day at 2 visits following washout of IOP-lowering medication, if applicable
- Qualifying best-corrected visual acuity in each eye
- Ability to provide informed consent and follow study instructions
Exclusion
- Narrow anterior chamber angles or disqualifying corneal thickness in either eye
- Clinically significant ocular disease in either eye
- Previous complicated surgery or certain types of glaucoma surgery in either eye
- Incisional ocular surgery or severe trauma in either eye within the past 6 months
- Uncontrolled systemic disease
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2022
Estimated Enrollment :
691 Patients enrolled
Trial Details
Trial ID
NCT04445519
Start Date
June 1 2020
End Date
September 16 2022
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Research Foundation
Newport Beach, California, United States, 92663